Your browser doesn't support javascript.
loading
Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia.
Weinhäuser, Isabel; Pereira-Martins, Diego A; Ortiz, Cesar; Silveira, Douglas R; Simões, Luíse A A; Bianco, Thiago M; Araujo, Cleide L; Koury, Luisa C; Melo, Raul A M; Bittencourt, Rosane I; Pagnano, Katia; Pasquini, Ricardo; Nunes, Elenaide C; Fagundes, Evandro M; Gloria, Ana B; Kerbauy, Fábio; Chauffaille, Maria de Lourdes; Keating, Armand; Tallman, Martin S; Ribeiro, Raul C; Dillon, Richard; Ganser, Arnold; Löwenberg, Bob; Valk, Peter; Lo-Coco, Francesco; Sanz, Miguel A; Berliner, Nancy; Ammatuna, Emanuele; Lucena-Araujo, Antonio R; Schuringa, Jan Jacob; Rego, Eduardo M.
Afiliação
  • Weinhäuser I; Department of Internal Medicine, Department of Medical Images, Hematology, and Clinical Oncology, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto 14048-900, Brazil.
  • Pereira-Martins DA; Center for Cell Based Therapy, University of São Paulo, Ribeirao Preto 14051-060, Brazil.
  • Ortiz C; Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
  • Silveira DR; Department of Internal Medicine, Department of Medical Images, Hematology, and Clinical Oncology, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto 14048-900, Brazil.
  • Simões LAA; Center for Cell Based Therapy, University of São Paulo, Ribeirao Preto 14051-060, Brazil.
  • Bianco TM; Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
  • Araujo CL; Department of Internal Medicine, Department of Medical Images, Hematology, and Clinical Oncology, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto 14048-900, Brazil.
  • Koury LC; Center for Cell Based Therapy, University of São Paulo, Ribeirao Preto 14051-060, Brazil.
  • Melo RAM; Hematology Division, LIM31, Faculdade de Medicina, University of Sao Paulo, Sao Paulo 05403-000, Brazil.
  • Bittencourt RI; Department of Hematology, AC Camargo Cancer Center, Sao Paulo 01525-001, Brazil.
  • Pagnano K; Center for Cell Based Therapy, University of São Paulo, Ribeirao Preto 14051-060, Brazil.
  • Pasquini R; Hematology Division, LIM31, Faculdade de Medicina, University of Sao Paulo, Sao Paulo 05403-000, Brazil.
  • Nunes EC; Department of Internal Medicine, Department of Medical Images, Hematology, and Clinical Oncology, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto 14048-900, Brazil.
  • Fagundes EM; Center for Cell Based Therapy, University of São Paulo, Ribeirao Preto 14051-060, Brazil.
  • Gloria AB; Department of Internal Medicine, Department of Medical Images, Hematology, and Clinical Oncology, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto 14048-900, Brazil.
  • Kerbauy F; Department of Internal Medicine, University of Pernambuco, Recife 50100-130, Brazil.
  • Chauffaille ML; Hematology Division, Federal University of Rio Grande do Sul, Porto Alegre 96.200-190, Brazil.
  • Keating A; Hematology and Hemotherapy Center, University of Campinas, Campinas 13083-878, Brazil.
  • Tallman MS; Hematology Division, Federal University of Parana, Curitiba 13083-878, Brazil.
  • Ribeiro RC; Hematology Division, Federal University of Parana, Curitiba 13083-878, Brazil.
  • Dillon R; Hematology Division, Federal University of Minas Gerais, Belo Horizonte 30130-100, Brazil.
  • Ganser A; Hematology Division, Federal University of Minas Gerais, Belo Horizonte 30130-100, Brazil.
  • Löwenberg B; Hematology Division, Federal University of Sao Paulo, Sao Paulo 04023-062, Brazil.
  • Valk P; Hematology Division, Federal University of Sao Paulo, Sao Paulo 04023-062, Brazil.
  • Lo-Coco F; Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.
  • Sanz MA; Leukemia Service, Memorial Sloan-Kettering Cancer Center/Weill Cornell Medical College, New York, NY 10065, USA.
  • Berliner N; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Ammatuna E; Department of Medical and Molecular Genetics, King's College London School of Medicine, London WC2R 2LS, UK.
  • Lucena-Araujo AR; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
  • Schuringa JJ; Department of Hematology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
  • Rego EM; Department of Hematology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Cancers (Basel) ; 12(11)2020 Oct 27.
Article em En | MEDLINE | ID: mdl-33120864
ABSTRACT
The SLIT-ROBO axis plays an important role in normal stem-cell biology, with possible repercussions on cancer stem cell emergence. Although the Promyelocytic Leukemia (PML) protein can regulate SLIT2 expression in the central nervous system, little is known about SLIT2 in acute promyelocytic leukemia. Hence, we aimed to investigate the levels of SLIT2 in acute promyelocytic leukemia (APL) and assess its biological activity in vitro and in vivo. Our analysis indicated that blasts with SLIT2high transcript levels were associated with cell cycle arrest, while SLIT2low APL blasts displayed a more stem-cell like phenotype. In a retrospective analysis using a cohort of patients treated with all-trans retinoic acid (ATRA) and anthracyclines, high SLIT2 expression was correlated with reduced leukocyte count (p = 0.024), and independently associated with improved overall survival (hazard ratio 0.94; 95% confidence interval 0.92-0.97; p < 0.001). Functionally, SLIT2-knockdown in primary APL blasts and cell lines led to increased cell proliferation and resistance to arsenic trioxide induced apoptosis. Finally, in vivo transplant of Slit2-silenced primary APL blasts promoted increased leukocyte count (p = 0.001) and decreased overall survival (p = 0.002) compared with the control. In summary, our data highlight the tumor suppressive function of SLIT2 in APL and its deteriorating effects on disease progression when downregulated.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Brasil

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Brasil